Metabolic Dysfunction-associated Steatohepatitis (MASH)
Conditions
Brief summary
The purpose of this study is to collect information for scientific research and to better understand awareness and to understand overall risk awareness, diagnoses and treatment related to liver related diseases. The study aims to collect valid responses through online questionnaires from the participants. This study is a survey-based study without collection of laboratory data. It will take the participant 25 minutes to complete the survey. The study is not related to any specific treatment options or pharmaceutical product.
Interventions
OTHERNo treatment given
No treatment given
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
HCP inclusion criteria * Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male or female, age above or equal to 18 years at the time of signing informed consent. * Licensed to practice medicine in one of the countries of interest: United States, Canada, France, Germany, Japan * Must be a practicing endocrinologist, hepatologist, cardiologist, obesity specialist, primary care physician, radiologist, nurse practitioner or physician assistant (NP/PA US only) * Must be at least "somewhat familiar" (as opposed to "not at all familiar) with Metabolic dysfunction-associated steatohepatitis (MASH) (do not need to be currently treating people with MASH) 6. Must have at least 2 years in practice 7. Must spend at least 50 percentage of their time in patient care Diagnosed patient inclusion criteria * Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male or female, age above or equal to 18 years at the time of signing informed consent. * Diagnosis of MASH or Metabolic Associated Steatotic Liver Disease (MASLD) within past 24 months * Live in one of the countries of interest: United States, Canada, France, Germany, Japan * Have at least one comorbid condition: obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease At risk patient inclusion criteria * Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male or female, age above or equal to 18 years at the time of signing informed consent. * Live in one of the countries of interest: United States, Canada, France, Germany, Japan * Must have one or more risk factors associated with MASH \[obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease\], be diagnosed with steatosis (incidental finding) or have a blood test that shows raised liver enzymes.
Exclusion criteria
* Previous participation in this study. Participation is defined as having given informed consent in this study * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Description of awareness, understanding, and perception of MASLD/MASH, comorbidities, and risk factors | At the time of survey (Day 1) | Healthcare Provider (HCP) Quantitative Segment 7-point Likert scale 1 indicates very strongly disagree and 7 indicates very strongly agree |
Countries
Canada, France, Germany, Japan, United States
Contacts
STUDY_DIRECTORClinical Transparency dept. 2834
Novo Nordisk A/S
Outcome results
None listed